Achilles Therapeutics: Promising Q1 2024 Results
Company Announcements

Achilles Therapeutics: Promising Q1 2024 Results

Achilles Therapeutics Plc (ACHL) has released an update.

Achilles Therapeutics Plc announced strong financial results for Q1 2024, with a cash reserve of $112.3 million, extending their operational runway through 2025. The company reported interim Phase I/IIa data on T cell therapies for advanced cancers, noting improvements and anticipating further data in the latter half of 2024. Research and development expenses decreased, contributing to a smaller net loss compared to the previous year.

For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.


Price Change
S&P 500
Dow Jones
Nasdaq 100

Popular Articles